{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bae JC"],"funding":["NIDDK NIH HHS","NCRR NIH HHS","NHLBI NIH HHS","National Institutes of Health"],"pagination":["633-641"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10922320"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(3)"],"pubmed_abstract":["<h4>Background and aims</h4>To prospectively investigate associations of plasma sphingolipids with insulin sensitivity, β-cell function, and incident diabetes in the Japanese American Community Diabetes Study.<h4>Methods and results</h4>Baseline plasma samples from adults without diabetes (n = 349; mean age 56.7 years, 51 % men) were assayed for circulating ceramide and sphingomyelin species. Adjusted regression models examined cross-sectional and longitudinal associations with insulin sensitivity (HOMA2-%S), β-cell function (oral disposition index: DIo) and with incident diabetes over 5 years follow-up. Concentrations of four species (Ceramide C16:0, C18:0, C20:0, and C22:0) were inversely associated with HOMA2-%S at baseline (all P values < 0.05, Q values < 0.05) and change in HOMA2-%S over 5 years (all P values < 0.05, Q values < 0.05). No sphingolipids were associated with baseline or change in DIo. Of the four species associated with HOMA2-%S, only Ceramide C18:0 was significantly and positively associated with incident diabetes (RR/1SD 1.44, 95 % CI 1.10-1.80, P = 0.006, Q = 0.024). The association of plasma Ceramide C18:0 with the risk of diabetes was partially mediated by change in HOMA2-%S between baseline and 5 years (mediation proportion: 61.5 %, 95 % CI 21.1%-212.5 %).<h4>Conclusion</h4>Plasma Ceramide C18:0 was associated with higher risk of incident diabetes which was partially mediated through a decrease in insulin sensitivity between baseline and five years. Circulating Ceramide C18:0 could be a potential biomarker for identifying those at risk of developing diabetes."],"journal":["Nutrition, metabolism, and cardiovascular diseases : NMCD"],"pubmed_title":["Associations of plasma sphingolipids with measures of insulin sensitivity, β-cell function, and incident diabetes in Japanese Americans."],"pmcid":["PMC10922320"],"funding_grant_id":["HL-049293","DK-017047","RR-000037","R01 DK031170","M01 RR000037","P30 DK017047","K24 DK002654","R01 HL049293","DK-002654","P30 DK035816","DK-031170","DK-035816"],"pubmed_authors":["Sitlani CM","Utzschneider KM","Thomas MK","Bae JC","Wander PL","Fujimoto WY","Boyko EJ","Lemaitre RN","Fretts AM","Bui HH","Leonetti D"],"additional_accession":[]},"is_claimable":false,"name":"Associations of plasma sphingolipids with measures of insulin sensitivity, β-cell function, and incident diabetes in Japanese Americans.","description":"<h4>Background and aims</h4>To prospectively investigate associations of plasma sphingolipids with insulin sensitivity, β-cell function, and incident diabetes in the Japanese American Community Diabetes Study.<h4>Methods and results</h4>Baseline plasma samples from adults without diabetes (n = 349; mean age 56.7 years, 51 % men) were assayed for circulating ceramide and sphingomyelin species. Adjusted regression models examined cross-sectional and longitudinal associations with insulin sensitivity (HOMA2-%S), β-cell function (oral disposition index: DIo) and with incident diabetes over 5 years follow-up. Concentrations of four species (Ceramide C16:0, C18:0, C20:0, and C22:0) were inversely associated with HOMA2-%S at baseline (all P values < 0.05, Q values < 0.05) and change in HOMA2-%S over 5 years (all P values < 0.05, Q values < 0.05). No sphingolipids were associated with baseline or change in DIo. Of the four species associated with HOMA2-%S, only Ceramide C18:0 was significantly and positively associated with incident diabetes (RR/1SD 1.44, 95 % CI 1.10-1.80, P = 0.006, Q = 0.024). The association of plasma Ceramide C18:0 with the risk of diabetes was partially mediated by change in HOMA2-%S between baseline and 5 years (mediation proportion: 61.5 %, 95 % CI 21.1%-212.5 %).<h4>Conclusion</h4>Plasma Ceramide C18:0 was associated with higher risk of incident diabetes which was partially mediated through a decrease in insulin sensitivity between baseline and five years. Circulating Ceramide C18:0 could be a potential biomarker for identifying those at risk of developing diabetes.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-18T13:31:19.489Z","creation":"2025-04-06T23:20:14.987Z"},"accession":"S-EPMC10922320","cross_references":{"pubmed":["38161124"],"doi":["10.1016/j.numecd.2023.10.026"]}}